**US Tariffs Could Impact India’s Pharmaceutical Sector, Warns Fitch Ratings**
India’s pharmaceutical industry, a significant contributor to the nation’s export earnings, may face challenges if the United States implements new tariffs, according to a recent report by Fitch Ratings. The agency highlighted that while Indian companies generally have limited direct exposure to existing US tariffs, the pharmaceutical sector remains particularly susceptible to potential future trade measures.
The US market is crucial for Indian drug manufacturers, and the introduction of tariffs could have widespread repercussions across the industry. Notably, Biocon Biologics Limited, which specializes in biosimilars, is at risk, with approximately 40% of its revenue derived from the US. The company primarily manufactures its products in India and Malaysia. Fitch cautioned that substantial US tariffs on pharmaceutical exports could adversely affect Biocon’s performance, as passing on increased costs to consumers may prove challenging in a competitive landscape, despite consistent demand for its products.
This warning follows the US government’s decision to impose a 25% reciprocal tariff on Indian goods starting August 7, 2025, along with an additional 25% levy on Russian oil imports effective August 27. These tariffs have already created uncertainty for various Indian industries. While the automobile and chemical sectors also face risks, their exposure is less pronounced compared to pharmaceuticals. For instance, Samvardhana Motherson International Limited, a supplier of auto components, generates nearly 20% of its sales from the US, primarily through its production facilities in the US and Mexico. Fitch recently adjusted the company’s outlook from “Positive” to “Stable,” citing uncertainties in the global automotive sector due to tariff disruptions.
Additionally, UPL Limited, a major player in crop protection, could experience challenges as well, with around 10-12% of its revenue coming from the US. Its products manufactured in India may be subject to tariffs similar to those imposed on Chinese imports.
The implications of these tariffs extend beyond manufacturing. Russian crude oil, which constitutes 30-40% of India’s oil imports, is vital for the profitability of state-owned oil marketing companies. Fitch estimates that a complete halt in Russian oil purchases could lead to a 10% decline in their earnings, although government support is expected to maintain their credit ratings.
Currently, Fitch anticipates limited direct tariff impacts on sectors such as IT services, cement, telecommunications, and utilities. However, the report warns that if tariffs remain higher than those in other Asian markets, India’s projected growth rate of 6.5% for FY26 could be jeopardized.
**FAQ**
**Q: How might US tariffs affect India’s pharmaceutical industry?**
A: US tariffs could significantly impact India’s pharmaceutical sector by increasing costs for companies like Biocon Biologics, which relies heavily on the US market for revenue. This could lead to challenges in maintaining profitability and competitiveness.
